FY22E preview; Bumpy recovery in 2023
Nayuki Holdings Limited (2150 HK) 期待 FY22E 的数字化
华润医药:1H22业绩巩固了FY22E的正面
FY22预计稳中向好,疫情无碍新财年起航,品牌韧性历经考验
Resilient FY22/1H23 despite industry headwinds
IMAX China(01970)FY22业绩会纪要-港股20230223-调研纪要
FY22 net margins better than expected
Outperforming FY22E, promising FY23E and not-far-fetching FY25E target
Hopson: weaker but much better than peers FY22
Yanlord:Resilient FY22 results and business model; maintain Buy